Huntsman Richard J, Elliott Jesse, Lewis Evan, Moore-Hepburn Charlotte, Alcorn Jane, Mansell Holly, Appendino Juan P, Bélanger Richard E, Corley Scott, Crooks Bruce, Denny AnneMarie M, Finkelstein Yaron, Finley Allen, Fung Ryan, Gilpin Andrea, Litalien Catherine, Jacobs Julia, Oberlander Timothy F, Palm Ashley, Palm Jacob, Polewicz Monika, Quinn Declan, Rassekh S Rod, Repetski Alexander, Rieder Michael J, Robson-McKay Amy, Seifert Blair, Shackelford Alan, Siden Hal, Szafron Michael, 't Jong Geert, Vaillancourt Régis, Kelly Lauren E
Division of Pediatric Neurology, Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Independent Researcher, Canadian Collaborative for Childhood Cannabinoid Therapeutics, Winnipeg, Manitoba, Canada.
Paediatr Child Health. 2023 Mar 31;29(1):12-16. doi: 10.1093/pch/pxac129. eCollection 2024 Feb.
Medical cannabis (MC) may offer therapeutic benefits for children with complex neurological conditions and chronic diseases. In Canada, parents, and caregivers frequently report encountering barriers when accessing MC for their children. These include negative preconceived notions about risks and benefits, challenges connecting with a knowledgeable healthcare provider (HCP), the high cost of MC products, and navigating MC product shortages. In this manuscript, we explore several of these barriers and provide recommendations to decision-makers to enable a family-centered and evidence-based approach to MC medicine and research for children.
医用大麻（MC）可能为患有复杂神经系统疾病和慢性病的儿童带来治疗益处。在加拿大，父母和照顾者经常报告称，在为孩子获取医用大麻时遇到障碍。这些障碍包括对风险和益处的负面先入之见、与知识渊博的医疗保健提供者（HCP）联系的挑战、医用大麻产品的高成本以及应对医用大麻产品短缺的问题。在本手稿中，我们探讨了其中的一些障碍，并向决策者提出建议，以实现以家庭为中心的、基于证据的儿童医用大麻医学和研究方法。
